Article Sidebar
Published:
Jul 8, 2026DOI:
10.4314/tjpr.v25i6.7Keywords:
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Synthesis, characterization, molecular docking and pharmacokinetics of new pyrimidine carboxylate derivatives as potent VEGFR inhibitors
Abstract
Purpose: To investigate the strategic design and synthesis of three new pyrimidine carboxylate derivatives aimed at inhibiting VEGFR signaling pathways to suppress tumor growth.
Methods: A set of 3 new pyrimidine carboxylate derivatives was successfully synthesized via optimized chemical routes. Structural integrity of the synthesized compounds was characterized using advanced spectroscopic techniques, including FT-IR, 1H-NMR, and 13C-NMR. Furthermore, multidimensional in silico investigations were conducted to evaluate therapeutic potential.
Results: According to the simulation of molecular docking, the three derivatives demonstrated a high potential for bonding in the vascular endothelial growth factor receptor (VEGFR) active site forming stable complex structures through a series of key hydrogen bond and hydrophobic interactions between important amino acid residues. Additionally, complete ADMET profiling indicated that the three compounds have excellent pharmacokinetic profiles and high oral bioavailability.
Conclusion: This study shows that the synthesized pyrimidine carboxylates bind effectively with VEGFR active site, demonstrate favourable pharmacokinetic properties and high oral bioavailability. Keywords:
